Catenacci, D. V. T., Park, H., Uronis, H. E., Kang, Y.-K., Ng, M., Gold, P., … Bang, Y.-J. (2018). Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). In Ann Oncol (Vol. 29 Suppl 8, p. viii223). England. https://doi.org/10.1093/annonc/mdy282.046

Catenacci, D. V. T., H. Park, H. E. Uronis, Y. -. K. Kang, M. Ng, P. Gold, J. Lacy, et al. “Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA).” In Ann Oncol, 29 Suppl 8:viii223, 2018. https://doi.org/10.1093/annonc/mdy282.046.

Catenacci DVT, Park H, Uronis HE, Kang Y-K, Ng M, Gold P, et al. Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). In: Ann Oncol. 2018. p. viii223.

Catenacci, D. V. T., et al. “Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA).” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii223. Pubmed, doi:10.1093/annonc/mdy282.046.

Catenacci DVT, Park H, Uronis HE, Kang Y-K, Ng M, Gold P, Lacy J, Enzinger PC, Park S, Lee K-W, Yen J, Odegaard J, Franovic A, Baughman J, Muth J, Wynter-Horton A, Wu T, Wigginton J, Davidson-Moncada JK, Bang Y-J. Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). Ann Oncol. 2018. p. viii223.